Overview

Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

Status:
Unknown status

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of Endostar (Recombinant Human Endostatin) combined with Docetaxel and single Docetaxel through multi-center, double-blinding, randomized controlled, phase Ⅳ clinical trial for NSCLC cases who have obvious progressive disease or intolerant adverse effects in first-line chemotherapy.

Phase:

Phase 4

Details

Lead Sponsor:

Simcere Pharmaceutical Co., Ltd

Treatments:

Docetaxel
Endostar protein
Endostatins